<?xml version="1.0" encoding="UTF-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xml:lang="en">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community</title>
        <author>Tommy Cederholm</author>
        <author>Gordon L. Jensen</author>
        <author>María Isabel Toulson Davisson Correia</author>
        <author>Marı́a Cristina González</author>
        <author>Ryoji Fukushima</author>
        <author>T. Higashiguchi</author>
        <author>Gertrudis Adrianza de Baptista</author>
        <author>Rocco Barazzoni</author>
        <author>Renée Blaauw</author>
        <author>Andrew J.S. Coats</author>
        <author>Adriana Crivelli</author>
        <author>David C. Evans</author>
        <author>Leah Gramlich</author>
        <author>Vanessa Fuchs‐Tarlovsky</author>
        <author>Heather Keller</author>
        <author>Luisito O. Llido</author>
        <author>Ainsley Malone</author>
        <author>Kris M. Mogensen</author>
        <author>John E. Morley</author>
        <author>Maurizio Muscaritoli</author>
        <author>Ibolya Nyulasi</author>
        <author>Matthias Pirlich</author>
        <author>Veeradej Pisprasert</author>
        <author>M.A.E. de van der Schueren</author>
        <author>S. Siltharm</author>
        <author>Pierre Singer</author>
        <author>Kelly A. Tappenden</author>
        <author>N Velasco</author>
        <author>Dan Linetzky Waitzberg</author>
        <author>Preyanuj Yamwong</author>
        <author>Jianchun Yu</author>
        <author>A. Van Gossum</author>
        <author>Charlene Compher</author>
      </titleStmt>
      <publicationStmt>
        <p>Tag layer of the DHSS Meta-Tagging Project. The article text is reproduced from the
           staged copy named in sourceDesc and is not altered; the tags are held separately in
           standOff so that overlapping and nested spans are preserved.</p>
      </publicationStmt>
      <sourceDesc>
        <bibl>
          <title>GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community</title>
          <date>2019</date>
          <publisher>Journal of Cachexia Sarcopenia and Muscle</publisher>
          <idno type="DOI">10.1002/jcsm.12383</idno>
          
          <idno type="record">cederholm2019-glim-criteria-for-the-diagnosis-of</idno>
          <note type="staged-file">cederholm2019-glim-criteria-for-the-diagnosis-of.txt, the project's staged copy</note>
          <note type="text-sha1">701187c443662e5689e61b68b1ffbf803342ed76</note>
          <note type="rights">cc-by</note>
        </bibl>
      </sourceDesc>
    </fileDesc>
    <profileDesc>
      <textClass><keywords><term>clinical medicine</term></keywords></textClass>
      <particDesc>
        <person xml:id="paper"><p>the paper's own words</p></person>
        <person xml:id="tagger"><p>the tag layer; a sentence written by the tagger about the
          paper, always anchored to a quotation but not itself a quotation</p></person>
      </particDesc>
    </profileDesc>
    <revisionDesc>
      <change when="2026-10-06"
              who="build_paper_edition.py">70 spans located by searching the stored text for the quote's exact words, allowing any whitespace between them</change>
    </revisionDesc>
  </teiHeader>
  <standOff>
    <spanGrp type="tags">
      <span xml:id="t0" from="#a1" to="#a2" type="object_of_study" ana="#object_of_study" resp="#paper">A DIAGNOSTIC DEFINITION CHOSEN BY BALLOT AND GIVEN AN EXPIRY DATE - the GLIM criteria for malnutrition, five criteria ranked by vote out of the eight competing tools already in use, requiring one phenotypic and one etiologic criterion, to be &#x27;re-considered every 3-5 years&#x27;</span>
      <span xml:id="t1" from="#a9" to="#a10" type="research_question" ana="#research_question" resp="#paper">how to give malnutrition one diagnostic definition usable worldwide, when eight existing approaches disagree and &#x27;no single existing approach has secured broad global acceptance&#x27;</span>
      <span xml:id="t2" from="#a27" to="#a28" type="contribution" ana="#contribution" resp="#paper">a two-step scheme - screen with any validated tool, then diagnose - with five balloted criteria split into phenotypic and etiologic, severity graded on the phenotypic side only, and four etiology-based diagnosis categories</span>
      <span xml:id="t3" from="#a1" to="#a2" type="claim_type" ana="#claim_type" resp="#paper">method</span>
      <span xml:id="t4" from="#a35" to="#a36" type="phenomenon" ana="#phenomenon" resp="#paper">undernutrition as a syndrome with several partly independent markers, none sufficient alone, overlapping three neighbouring constructs - cachexia, sarcopenia and frailty - that the new definition declines to absorb</span>
      <span xml:id="t5" from="#a13" to="#a14" type="method" ana="#method" resp="#paper">expert-consensus<term>expert-consensus</term></span>
      <span xml:id="t6" from="#a1" to="#a2" type="mechanisms" ana="#mechanisms[0]" resp="#tagger" cert="0.95">A DEFINITION CHOSEN BY BALLOT: `The malnutrition criteria for consideration were retrieved from existing approaches for screening and assessment. Potential criteria were subjected to a ballot among the GLIM core and supporting working group members. The top five ranked criteria included three phenotypic criteria (weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria.` The candidates came from what was already in use and the cut was a vote count - the corpus&#x27;s other consensus papers vote on a proposal; this one ranks a field</span>
      <span xml:id="t7" from="#a5" to="#a6" type="mechanisms" ana="#mechanisms[1]" resp="#tagger" cert="0.95">AND THE DEFINITION HAS AN EXPIRY DATE: `The diagnostic construct should be re-considered every 3-5 years.` Repeated in the conclusion - `The GLIM consensus should be re-evaluated based upon review of new studies and advances in screening and assessment every 3-5 years.` A definition that schedules its own replacement. polman2011 revised the McDonald criteria three times without ever saying when the next revision was due; this one puts it in the abstract</span>
      <span xml:id="t8" from="#a43" to="#a44" type="mechanisms" ana="#mechanisms[2]" resp="#tagger" cert="0.95">AND THE SAME DOCUMENT IS PUBLISHED THREE TIMES, `substantially the same`: `This article was first co-published in the journal Clinical Nutrition and in the Journal of Parenteral and Enteral Nutrition and is re-published here. Minor differences in style may appear in each publication, but the article is substantially the same in each journal.` Three published copies of one criteria set, none of them authoritative over the others - anyone citing `the GLIM criteria` is citing one of three documents and the citation cannot say which</span>
      <span xml:id="t9" from="#a15" to="#a16" type="mechanisms" ana="#mechanisms[3]" resp="#tagger" cert="0.95">AND ONE CRITERION CARRIES A DIFFERENT THRESHOLD BY CONTINENT, ON PURPOSE: `There is substantial regional variation in the use of low BMI ... North American GLIM representatives indicated that low BMI is seldom used as a clinical malnutrition marker in those regions ... Since other regions of the world currently make use of BMI as a criterion ..., the GLIM consensus includes low BMI. Further research is however needed to secure consensus reference BMI data for Asian populations.` The published table carries both: `&lt;20 if &lt;70 years` and `Asia: &lt;18.5 if &lt;70 years`. The exact opposite trade from li2020, which held one HbA1c threshold across all of China `TO ENABLE COMPARISON` although it `WAS SET FOR THE US POPULATION`</span>
      <span xml:id="t10" from="#a17" to="#a18" type="mechanisms" ana="#mechanisms[4]" resp="#tagger" cert="0.95">AND THE CRITERION WITH THE STRONGEST EVIDENCE HAS THE WEAKEST MEASUREMENT: `Reduced muscle mass is a phenotypic criterion with strong evidence to support its inclusion ... However, there is not consensus regarding how best to measure and define reduced muscle mass, particularly in clinical settings ... these methods are still not available in most settings for nutritional assessment throughout the globe.` Agreement that it matters and disagreement about how to see it - so the criteria list a hierarchy of substitutes down to `calf or arm muscle circumference`</span>
      <span xml:id="t11" from="#a19" to="#a20" type="mechanisms" ana="#mechanisms[5]" resp="#tagger" cert="0.85">AND THE CUT-OFFS FOR THAT CRITERION ARE BORROWED FROM THREE OTHER WORKING GROUPS: `GLIM refers to recommendations from the European Working Group on Sarcopenia in Older People (EWGSOP) and from The Foundation of National Institute of Health (FNIH) initiative, and the Asian Working Group on Sarcopenia (AWGS). Reference standards for muscle mass may warrant adjustment for race and sex.` A malnutrition definition importing its thresholds from the sarcopenia literature - which is why the two constructs then have to be told apart in the discussion</span>
      <span xml:id="t12" from="#a35" to="#a36" type="mechanisms" ana="#mechanisms[6]" resp="#tagger" cert="0.95">AND THE NEW DEFINITION IS EXPLICITLY NOT REPLACING ITS NEIGHBOURS: `patients with cachexia will meet GLIM consensus criteria for malnutrition related to chronic disease with inflammation. Since there is concern that inclusion of cachexia ... may diminish appreciation for some distinctive features of cachexia, there has been understandable hesitation by some to equate cachexia with this GLIM diagnosis category. The GLIM consensus criteria for malnutrition are therefore intended to be used in parallel with established concepts and nomenclature, including ... cachexia, sarcopenia and frailty.` A definition that subsumes its neighbours extensionally and refuses to replace them nominally</span>
      <span xml:id="t13" from="#a33" to="#a34" type="mechanisms" ana="#mechanisms[7]" resp="#tagger" cert="0.85">AND THE FIELD DEPARTS FROM ITS PARENT CLASSIFICATION DELIBERATELY: `While etiology has not generally been included in criteria supporting the diagnosis of medical conditions in the ICD construct, the inclusion of etiology has been widely adopted in the clinical nutrition community because it serves to guide appropriate interventions and expected outcomes.` A discipline knowingly using a different kind of criterion from the classification it wants to be adopted into - and the conclusion then asks WHO to take it into ICD-11</span>
      <span xml:id="t14" from="#a41" to="#a42" type="mechanisms" ana="#mechanisms[8]" resp="#tagger" cert="0.95">AND THE REASON THAT MATTERS IS MONEY: `We will also seek to share the GLIM consensus recommendations with the World Health Organization in the context of the International Classification of Diseases revision process (ICD-11). This is a high priority since this classification scheme guides clinical diagnosis and reimbursement across much of the world.` The stated destination of a definition is a payment system, which is the clearest statement in the corpus of what adoption is actually for</span>
      <span xml:id="t15" from="#a27" to="#a28" type="mechanisms" ana="#mechanisms[9]" resp="#tagger" cert="0.95">AND SEVERITY IS GRADED ON ONE HALF OF THE DEFINITION ONLY: `Weight loss, reduced BMI, and reduced muscle mass were categorized as phenotypic criteria, and reduced food intake/assimilation and disease burden/inflammation as etiologic criteria ... While only the phenotypic criteria are proposed for the severity grading that follows, the inclusion of the etiologic criteria for malnutrition diagnosis is deemed a priority to guide appropriate intervention.` One half decides whether, the other half decides what to do about it - and only the first half is measured on a scale</span>
      <span xml:id="t16" from="#a39" to="#a40" type="mechanisms" ana="#mechanisms[10]" resp="#tagger" cert="0.95">AND THE VALIDATION IS SCHEDULED AFTER PUBLICATION: `After the launch of the GLIM consensus it is important that the nutrition community use the criteria both in prospective and retrospective cohort studies as well as clinical trials in order to validate its relevance for clinical practice. Next steps are to secure endorsements from leading nutrition professional societies and to promote dissemination, validation testing, and feedback.` Endorsement and validation are listed as parallel next steps, in that order</span>
      <span xml:id="t17" from="#a39" to="#a40" type="limitations" ana="#limitations[0]" resp="#tagger" cert="0.95">THE CRITERIA ARE PUBLISHED BEFORE THEY ARE VALIDATED, AND THE PAPER SAYS SO: `After the launch of the GLIM consensus it is important that the nutrition community use the criteria ... in order to validate its relevance for clinical practice.` The supporting evidence offered is that `each of them ALONE is able to predict adverse clinical outcomes` - which is evidence for the components, not for the conjunction that the definition actually requires</span>
      <span xml:id="t18" from="#a17" to="#a18" type="limitations" ana="#limitations[1]" resp="#tagger" cert="0.95">AND THE MOST EVIDENCED CRITERION CANNOT BE MEASURED IN MOST PLACES: `GLIM recommends measurement by dual-energy absorptiometry or other validated body composition measures ..., but these methods are still not available in most settings for nutritional assessment throughout the globe. Physical examination or anthropometric measures of calf or arm muscle circumference are therefore included as alternative measures.` A global definition has to be satisfiable with a tape measure, and the alternatives are not equivalent to the recommended method</span>
      <span xml:id="t19" from="#a25" to="#a26" type="limitations" ana="#limitations[2]" resp="#tagger" cert="0.95">AND ONE ETIOLOGIC CRITERION RESTS ON CLINICAL JUDGEMENT BY ADMISSION: `While severe inflammation is generally easy to discern, clinical judgement is often required to recognize that of lesser degree. Supportive proxy measures ... can include laboratory indicators like serum C-reactive protein, albumin, or pre-albumin.` The mild-to-moderate band - which covers most chronic disease - has no threshold at all, only proxies described as supportive</span>
      <span xml:id="t20" from="#a27" to="#a28" type="limitations" ana="#limitations[3]" resp="#tagger" cert="0.95">AND THE THRESHOLDS WERE SELECTED BY REVIEW RATHER THAN DERIVED: `The selection of threshold values for the consensus diagnostic criteria was guided by review of existing approaches used in screening and assessment as was the selection of threshold values for severity grading.` The appendix prints the eight source tools&#x27; cut-offs side by side; the GLIM numbers are a synthesis of those, not a measurement, and the paper does not claim otherwise</span>
      <span xml:id="t21" from="#a15" to="#a16" type="limitations" ana="#limitations[4]" resp="#tagger" cert="0.95">AND THE REGIONAL BMI THRESHOLD IS FLAGGED AS UNFINISHED IN THE SAME BREATH AS IT IS PUBLISHED: `Further research is however needed to secure consensus reference BMI data for Asian populations in clinical settings` - while `Asia: &lt;18.5 if &lt;70 years, or &lt;20 if &gt;70 years` is already in the criteria table</span>
      <span xml:id="t22" from="#a27" to="#a28" type="controls" ana="#controls[0]" resp="#tagger" cert="0.95">requiring one criterion from EACH half rather than any N of five<note>eliminates: a diagnosis made on phenotype alone, which would not distinguish malnutrition from constitutional thinness, or on cause alone with no manifestation · outcome: held</note></span>
      <span xml:id="t23" from="#a29" to="#a30" type="controls" ana="#controls[1]" resp="#tagger" cert="0.95">excluding the etiologic criteria from severity grading<note>eliminates: a severity score that moves with the diagnosis behind the malnutrition rather than with the patient&#x27;s state · outcome: held</note></span>
      <span xml:id="t24" from="#a15" to="#a16" type="controls" ana="#controls[2]" resp="#tagger" cert="0.85">carrying a separate BMI threshold for Asian populations instead of one global cut<note>eliminates: a criterion that misclassifies whole regions because it was set elsewhere · outcome: partial</note></span>
      <span xml:id="t25" from="#a35" to="#a36" type="controls" ana="#controls[3]" resp="#tagger" cert="0.95">keeping cachexia, sarcopenia and frailty as separate nomenclature to be used in parallel<note>eliminates: a broad new category absorbing three established ones and losing what each was for · outcome: held</note></span>
      <span xml:id="t26" from="#a27" to="#a28" type="concepts" ana="#concepts[0]" resp="#paper" cert="0.95">phenotypic criteria<term>phenotypic criteria</term></span>
      <span xml:id="t27" from="#a27" to="#a28" type="concepts" ana="#concepts[1]" resp="#paper" cert="0.95">etiologic criteria<term>etiologic criteria</term></span>
      <span xml:id="t28" from="#a27" to="#a28" type="concepts" ana="#concepts[2]" resp="#paper" cert="0.95">Weight loss<term>Weight loss</term></span>
      <span xml:id="t29" from="#a35" to="#a36" type="concepts" ana="#concepts[3]" resp="#paper" cert="0.95">cachexia<term>cachexia</term></span>
      <span xml:id="t30" from="#a35" to="#a36" type="concepts" ana="#concepts[4]" resp="#paper" cert="0.95">this GLIM diagnosis category<term>this GLIM diagnosis category</term></span>
      <span xml:id="t31" from="#a7" to="#a8" type="concepts" ana="#concepts[5]" resp="#paper" cert="0.95">Inflammation<term>Inflammation</term></span>
      <span xml:id="t32" from="#a7" to="#a8" type="concepts" ana="#concepts[6]" resp="#paper" cert="0.95">malnutrition<term>malnutrition</term></span>
      <span xml:id="t33" from="#a31" to="#a32" type="concepts" ana="#concepts[7]" resp="#paper" cert="0.85">The classification<term>The classification</term></span>
      <span xml:id="t34" from="#a31" to="#a32" type="concepts" ana="#concepts[8]" resp="#paper" cert="0.85">malnutrition related to chronic disease with inflammation<term>malnutrition related to chronic disease with inflammation</term></span>
      <span xml:id="t35" from="#a27" to="#a28" type="senses" ana="#senses[0]" resp="#tagger" cert="0.95">`malnutrition` (GLIM) - at least ONE phenotypic criterion (weight loss, low BMI, reduced muscle mass) AND at least ONE etiologic criterion (reduced intake or assimilation, inflammation or disease burden)</span>
      <span xml:id="t36" from="#a3" to="#a4" type="senses" ana="#senses[1]" resp="#tagger" cert="0.95">`phenotypic criterion` - what the body shows; the only half used for severity grading into Stage 1 (moderate) and Stage 2 (severe)</span>
      <span xml:id="t37" from="#a27" to="#a28" type="senses" ana="#senses[2]" resp="#tagger" cert="0.95">`etiologic criterion` - why it happened; required for diagnosis, excluded from grading, and kept `to guide appropriate intervention and anticipated outcomes`</span>
      <span xml:id="t38" from="#a11" to="#a12" type="senses" ana="#senses[3]" resp="#tagger" cert="0.95">`at risk` - the output of step one, established `by the use of any validated screening tool`; the definition deliberately does not name which</span>
      <span xml:id="t39" from="#a31" to="#a32" type="senses" ana="#senses[4]" resp="#tagger" cert="0.85">the four etiology-based categories - chronic disease WITH inflammation, chronic disease with MINIMAL OR NO perceived inflammation, ACUTE disease or injury with severe inflammation, and STARVATION including hunger and food shortage</span>
      <span xml:id="t40" from="#a13" to="#a14" type="claim_relations" ana="#claim_relations[0]" resp="#tagger" cert="0.95">extends → the eight existing screening and assessment approaches surveyed in Table 1 - NRS-2002, MNA-SF, MUST, ESPEN 2015, ASPEN/AND, SGA, Evans 2008, PEW 2008 and Fearon 2011 - from which the candidate criteria were drawn</span>
      <span xml:id="t41" from="#a19" to="#a20" type="claim_relations" ana="#claim_relations[1]" resp="#tagger" cert="0.85">extends → the EWGSOP, FNIH and AWGS sarcopenia working groups, whose muscle-mass cut-offs GLIM adopts wholesale</span>
      <span xml:id="t42" from="#a9" to="#a10" type="claim_relations" ana="#claim_relations[2]" resp="#tagger" cert="0.95">critiques → the ICD-10 concepts of malnutrition, which our &#x27;evolving understanding of the contributions of disease/inflammation may render ... inconsistent with approaches or nomenclature that are currently used&#x27;</span>
      <span xml:id="t43" from="#a35" to="#a36" type="claim_relations" ana="#claim_relations[3]" resp="#tagger" cert="0.95">critiques → equating cachexia with the GLIM chronic-disease-with-inflammation category, which &#x27;may diminish appreciation for some distinctive features of cachexia&#x27;</span>
      <span xml:id="t44" from="#a27" to="#a28" type="concept_edges" ana="#concept_edges[0]" resp="#tagger" cert="0.95">phenotypic criteria —distinct-from→ etiologic criteria<note>the relation itself is separately evidenced · strength of the relation: 0.95 · note: &#x27;While only the phenotypic criteria are proposed for the severity grading that follows, the inclusion of the etiologic criteria for malnutrition diagnosis is deemed a priority to guide appropriate intervention and anticipated outcomes.&#x27; A definition split by what each half is FOR - one answers &#x27;is this malnutrition and how bad&#x27;, the other answers &#x27;what should be done&#x27;, and the ICD construct does not normally admit the second at all · the relation stated: the phenotypic half decides severity and the etiologic half decides treatment; both are required for diagnosis and only the first is graded</note><term>phenotypic criteria</term><term>etiologic criteria</term></span>
      <span xml:id="t45" from="#a27" to="#a28" type="concept_edges" ana="#concept_edges[1]" resp="#tagger" cert="0.95">Weight loss —is-a→ phenotypic criteria<note>the relation itself is separately evidenced · strength of the relation: 0.95 · note: &#x27;Weight loss, reduced BMI, and reduced muscle mass were categorized as phenotypic criteria, and reduced food intake/assimilation and disease burden/inflammation as etiologic criteria.&#x27; The assignment is the definition&#x27;s structure, and it was made after the ballot ranked the five - the vote chose the members, the panel chose the partition · the relation stated: weight loss, reduced BMI and reduced muscle mass are the phenotypic criteria; reduced intake and inflammation are the etiologic ones</note><term>Weight loss</term><term>phenotypic criteria</term></span>
      <span xml:id="t46" from="#a35" to="#a36" type="concept_edges" ana="#concept_edges[2]" resp="#tagger" cert="0.95">cachexia —contrasted-with→ this GLIM diagnosis category<note>the relation itself is separately evidenced · strength of the relation: 0.95 · note: &#x27;Since there is concern that inclusion of cachexia with other disease-related malnutrition conditions may diminish appreciation for some distinctive features of cachexia, there has been understandable hesitation by some to equate cachexia with this GLIM diagnosis category.&#x27; Extensional overlap without nominal merger - the criteria are &#x27;intended to be used in parallel with established concepts and nomenclature&#x27;, which is a fourth option beside abolish, redefine and keep · the relation stated: cachectic patients satisfy the GLIM category, and the two are deliberately not equated because the category would lose what is distinctive about cachexia
Audit 2026-09-28: DOUBTFUL - read against its full span and kept, but some hesitate to EQUATE cachexia with this GLIM category; contrasted-with is loose.</note><term>cachexia</term><term>this GLIM diagnosis category</term></span>
      <span xml:id="t47" from="#a7" to="#a8" type="concept_edges" ana="#concept_edges[3]" resp="#tagger" cert="0.95">Inflammation —causes→ malnutrition<note>the relation itself is separately evidenced · strength of the relation: 0.95 · note: &#x27;Inflammation contributes to malnutrition through associated anorexia and decreased food intake as well as altered metabolism with elevation of resting energy expenditure and increased muscle catabolism.&#x27; The causal claim is what makes inflammation an ETIOLOGIC rather than a phenotypic criterion - it is in the definition because of what it does, not because of what it shows · the relation stated: inflammation produces malnutrition through anorexia and reduced intake, raised resting energy expenditure and increased muscle catabolism</note><term>Inflammation</term><term>malnutrition</term></span>
      <span xml:id="t48" from="#a31" to="#a32" type="concept_edges" ana="#concept_edges[4]" resp="#tagger" cert="0.85">malnutrition related to chronic disease with inflammation —part-of→ The classification<note>the relation itself is separately evidenced · strength of the relation: 0.9 · note: &#x27;The classification includes malnutrition related to chronic disease with inflammation, malnutrition related to chronic disease with minimal or no perceived inflammation, malnutrition related to acute disease or injury with severe inflammation, and malnutrition related to starvation including hunger/food shortage associated with socioeconomic or environmental factors.&#x27; Four categories cut by CAUSE, three of them by inflammation and one by having none of it · the relation stated: the etiology-based classification holds four categories, of which chronic disease with inflammation is the one cachexia falls into</note><term>malnutrition related to chronic disease with inflammation</term><term>The classification</term></span>
      <span xml:id="t49" from="#a1" to="#a2" type="content_tags" ana="#content_tags.findings[0]" resp="#tagger" cert="0.95">A DEFINITION CHOSEN BY BALLOT: `Potential criteria were subjected to a ballot ... The top five ranked criteria included three phenotypic criteria ... and two etiologic criteria`<term>A DEFINITION CHOSEN BY BALLOT: `Potential criteria were subjected to a ballot ... The top five ranked criteria included three phenotypic criteria ... and two etiologic criteria`</term></span>
      <span xml:id="t50" from="#a5" to="#a6" type="content_tags" ana="#content_tags.findings[1]" resp="#tagger" cert="0.95">AND IT HAS AN EXPIRY DATE: `The diagnostic construct should be re-considered every 3-5 years` - a definition that schedules its own replacement<term>AND IT HAS AN EXPIRY DATE: `The diagnostic construct should be re-considered every 3-5 years` - a definition that schedules its own replacement</term></span>
      <span xml:id="t51" from="#a43" to="#a44" type="content_tags" ana="#content_tags.findings[2]" resp="#tagger" cert="0.95">the article was co-published in three journals with minor style differences but is substantially the same<term>the article was co-published in three journals with minor style differences but is substantially the same</term></span>
      <span xml:id="t52" from="#a15" to="#a16" type="content_tags" ana="#content_tags.findings[3]" resp="#tagger" cert="0.95">low BMI is seldom used as a malnutrition marker in North America, but GLIM includes it because other regions use it<term>low BMI is seldom used as a malnutrition marker in North America, but GLIM includes it because other regions use it</term></span>
      <span xml:id="t53" from="#a17" to="#a18" type="content_tags" ana="#content_tags.findings[4]" resp="#tagger" cert="0.95">AND THE BEST-EVIDENCED CRITERION HAS NO AGREED MEASUREMENT: `there is not consensus regarding how best to measure and define reduced muscle mass` and the recommended methods are `still not available in most settings`<term>AND THE BEST-EVIDENCED CRITERION HAS NO AGREED MEASUREMENT: `there is not consensus regarding how best to measure and define reduced muscle mass` and the recommended methods are `still not available in most settings`</term></span>
      <span xml:id="t54" from="#a19" to="#a20" type="content_tags" ana="#content_tags.findings[5]" resp="#tagger" cert="0.85">AND ITS CUT-OFFS ARE BORROWED FROM THE SARCOPENIA WORKING GROUPS: `GLIM refers to recommendations from ... (EWGSOP) and ... (FNIH) ..., and the Asian Working Group on Sarcopenia (AWGS)`<term>AND ITS CUT-OFFS ARE BORROWED FROM THE SARCOPENIA WORKING GROUPS: `GLIM refers to recommendations from ... (EWGSOP) and ... (FNIH) ..., and the Asian Working Group on Sarcopenia (AWGS)`</term></span>
      <span xml:id="t55" from="#a35" to="#a36" type="content_tags" ana="#content_tags.findings[6]" resp="#tagger" cert="0.95">the GLIM criteria are intended to be used in parallel with established concepts such as cachexia, sarcopenia and frailty<term>the GLIM criteria are intended to be used in parallel with established concepts such as cachexia, sarcopenia and frailty</term></span>
      <span xml:id="t56" from="#a33" to="#a34" type="content_tags" ana="#content_tags.findings[7]" resp="#tagger" cert="0.85">AND THE FIELD DEPARTS FROM ICD ON PURPOSE: `While etiology has not generally been included ... in the ICD construct, the inclusion of etiology has been widely adopted in the clinical nutrition community`<term>AND THE FIELD DEPARTS FROM ICD ON PURPOSE: `While etiology has not generally been included ... in the ICD construct, the inclusion of etiology has been widely adopted in the clinical nutrition community`</term></span>
      <span xml:id="t57" from="#a41" to="#a42" type="content_tags" ana="#content_tags.findings[8]" resp="#tagger" cert="0.95">sharing GLIM with WHO for ICD-11 is a high priority because ICD guides diagnosis and reimbursement<term>sharing GLIM with WHO for ICD-11 is a high priority because ICD guides diagnosis and reimbursement</term></span>
      <span xml:id="t58" from="#a27" to="#a28" type="content_tags" ana="#content_tags.definitions[0]" resp="#tagger" cert="0.95">`at least 1 phenotypic criterion and 1 etiologic criterion` from five balloted criteria, after screening `at risk` with any validated tool<term>malnutrition (GLIM)</term></span>
      <span xml:id="t59" from="#a31" to="#a32" type="content_tags" ana="#content_tags.definitions[2]" resp="#tagger" cert="0.85">chronic disease WITH inflammation; chronic disease with MINIMAL OR NO perceived inflammation; ACUTE disease or injury with severe inflammation; STARVATION<term>etiology-based diagnosis classification</term></span>
      <span xml:id="t60" from="#a17" to="#a18" type="content_tags" ana="#content_tags.definitions[3]" resp="#tagger" cert="0.95">`there is not consensus regarding how best to measure and define` it - DXA, BIA, ultrasound, CT or MRI where available, calf or arm circumference where not<term>reduced muscle mass</term></span>
      <span xml:id="t61" from="#a1" to="#a2" type="content_tags" ana="#content_tags.quantities[0]" resp="#tagger" cert="0.95">`by an overwhelming majority of GLIM participants`, with the candidate set drawn from eight existing tools<term>the ballot</term></span>
      <span xml:id="t62" from="#a1" to="#a2" type="content_tags" ana="#content_tags.quantities[1]" resp="#tagger" cert="0.95">severity graded on the phenotypic side only, into Stage 1 (moderate) and Stage 2 (severe)<term>the diagnostic rule</term></span>
      <span xml:id="t63" from="#a23" to="#a24" type="content_tags" ana="#content_tags.quantities[2]" resp="#tagger" cert="0.95">`Further research is however needed to secure consensus reference BMI data for Asian populations`, published alongside the number<note>about this quote: THIS QUOTE IS A RUN OF TABLE 1 (GLIM phenotypic criteria), read cell by cell: the low-BMI thresholds, then the reduced-muscle-mass, food-intake and inflammation cells, then the thresholds for Asia.</note><term>the BMI thresholds</term></span>
      <span xml:id="t64" from="#a5" to="#a6" type="content_tags" ana="#content_tags.quantities[3]" resp="#tagger" cert="0.95">stated twice - in the abstract and in the conclusion<term>the review interval</term></span>
      <span xml:id="t65" from="#a37" to="#a38" type="content_tags" ana="#content_tags.statistics[0]" resp="#tagger" cert="0.95">`Many studies provide clear evidence that the agreed upon criteria ... are highly relevant and each of them alone is able to predict adverse clinical outcomes.` The definition requires a conjunction of two criteria and the cited evidence is for each separately - which is the same gap carroll2007 names when a field measures one element of five<term>evidence for the components, not for the conjunction</term></span>
      <span xml:id="t66" from="#a27" to="#a28" type="content_tags" ana="#content_tags.statistics[1]" resp="#tagger" cert="0.95">`The selection of threshold values for the consensus diagnostic criteria was guided by review of existing approaches` - the appendix prints eight tools&#x27; cut-offs side by side and the GLIM numbers sit among them<term>thresholds selected by review rather than derived</term></span>
      <span xml:id="t67" from="#a25" to="#a26" type="content_tags" ana="#content_tags.variables[0]" resp="#tagger" cert="0.95">the etiologic criterion with no threshold for its commonest band - `clinical judgement is often required to recognize that of lesser degree`, with CRP, albumin and pre-albumin as supportive proxies only<term>inflammation</term></span>
      <span xml:id="t68" from="#a21" to="#a22" type="content_tags" ana="#content_tags.variables[1]" resp="#tagger" cert="0.95">measured by DXA, BIA, ultrasound, CT or MRI where available and by `calf or arm muscle circumference` where not - with grip strength as a `supporting proxy`<term>muscle mass</term></span>
      <span xml:id="t69" from="#a15" to="#a16" type="content_tags" ana="#content_tags.variables[2]" resp="#tagger" cert="0.95">a variable inside the definition itself: the BMI cut-off changes for Asia, and muscle-mass reference standards `may warrant adjustment for race and sex`<term>region</term></span>
    </spanGrp>
  </standOff>
  <text>
    <body>
        <p><anchor xml:id="a0"/> 1721 cachex Journal of Cachexia, Sarcopenia and Muscle J Cachexia Sarcopenia Muscle Wiley PMC6438340 6438340 6438340 30920778 10.1002/jcsm.12383 GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community *   Cederholm T 1 2 † ✉ Jensen GL 3 † Correia MITD 4 Gonzalez MC 5 Fukushima R 6 Higashiguchi T 7 Baptista G 8 Barazzoni R 9 Blaauw R 10 Coats AJS 11 12 Crivelli AN 13 Evans DC 14 Gramlich L 15 Fuchs‐Tarlovsky V 16 Keller H 17 Llido L 18 Malone A 19 20 Mogensen KM 21 Morley JE 22 Muscaritoli M 23 Nyulasi I 24 Pirlich M 25 Pisprasert V 26 de van der Schueren MAE 27 28 Siltharm S 29 Singer P 30 31 Tappenden K 32 Velasco N 33 Waitzberg D 34 Yamwong P 35 Yu J 36 Van Gossum A 37 ‡ Compher C 38 ‡ GLIM Core Leadership Committee, GLIM Working Group § 1 Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala, Sweden 2 Theme Aging, Karolinska University Hospital, Stockholm, Sweden 3 Dean&#x27;s Office and Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA 4 Department of Surgery, Universidade Federal de Minas Gerais, Belo Horizante, Brazil 5 Post‐graduate Program in Health and Behavior, Catholic University of Pelotas, RS, Brazil 6 Department of Medicine, Department of Surgery, Tokyo University School of Medicine, Tokyo, Japan 7 Department of Surgery and Palliative Medicine, Fujita Health University School of Medicine, Dengakugakubo, Kutsukake, Toyoake‐City, Aichi, Japan 8 Medicine Faculty Central University of Venezuela, Universitary Hospital of Caracas, Chief Nutritional Support Unit Hospital Universitary/Academic of Caracas, University Central of Venezuela, Venezuela 9 Department of Medical, Technological and Translational Sciences, University of Trieste, Ospedale di Cattinara, Trieste, Italy 10 Division of Human Nutrition, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa 11 Monash University, Australia 12 University of Warwick, Warwick, UK 13 Unit of Nutrition Support and Malabsorptive Diseases, Hospital HIGA San Martín, Buenos Aires, Argentina 14 Department of Surgery, The Ohio State University, Columbus, OH, USA 15 University of Alberta, Edmonton, Alberta, Canada 16 Clinical Nutrition Department, Hospital General de México, Mexico City, Mexico 17 Schlegel‐UW Research Institute for Aging and Department of Kinesiology, University of Waterloo, Ontario, Canada 18 Clinical Nutrition Service, St. Luke&#x27;s Medical Center‐Quezon City, Metro‐Manila, Quezon City, Philippines 19 The American Society for Parenteral and Enteral Nutrition, Silver Spring, MD, USA 20 Mt. Carmel West Hospital, Columbus, OH, USA 21 Department of Nutrition, Brigham and Women&#x27;s Hospital, Boston, MA, USA 22 Division of Geriatrics, Saint Louis University Hospital, St. Louis, MO, USA 23 Department of Clinical Medicine, Sapienza University of Rome, Italy 24 Department of Nutrition, Alfred Health and Professor of Dietetic Practice, Department of Rehabilitation, Nutrition and Sport, Latrobe University; Department of Medicine, Central Clinical School, Monash University, Australia 25 Imperial Oak Outpatient Clinic, Endocrinology, Gastroenterology and Clinical Nutrition, Berlin, Germany 26 Department of Medicine, Khon Kaen University College of Medicine, Khon Kaen, Thailand 27 Department of Nutrition and Dietetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands 28 Faculty of Health and Social Studies, Department of Nutrition and Dietetics, HAN University of Applied Sciences, Nijmegen, the Netherlands 29 Ministry of Science and Technology, Bangkok, Thailand 30 Department of General Intensive Care, Rabin Medical Center, Petah Tikva, Israel 31 Sackler School of Medicine, Tel Aviv University, Israel 32 Department of Kinesiology and Nutrition, University of Illinois‐Chicago, Chicago, IL, USA 33 Department of Nutrition, Diabetes and Metabolismo, School of Medicine, Pontificia Universidad Catolica de Chile, Chile 34 Department of Gastroenterology, School of Medicine, University of São Paulo, São Paulo, Brazil 35 Department of Medicine, Siriaj Hospital, Bangkok, Thailand 36 GI Surgery and Nutrition Metabolic Division, Department of General Surgery, Peking Union Medical College Hospital, Beijing, China 37 Department of Gastroenterology, Clinic of Intestinal Diseases and Nutritional Support, Hopital Erasme, Free University of Brussels, Brussels, Belgium 38 Biobehavioral Health Sciences Department and Nutrition Programs, University of Pennsylvania School of Nursing, Philadelphia, PA, USA * Correspondence to: Tommy Cederholm, Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala, Sweden. Email: tommy.cederholm@pubcare.uu.se</p>
        <p>§  Members of the GLIM Core Leadership Committee and GLIM Working Group are listed at the end of the article.</p>
        <p>†  Contributed equally.</p>
        <p>‡  Contributed equally.</p>
        <p>✉ Corresponding author.</p>
        <p>28 3 2019 10 1 207 207–217 11 4 2019 © 2018 Elsevier Ltd, the European Society for Clinical Nutrition and Metabolism and American Society for Parenteral and Enteral Nutrition. All rights reserved This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Summary</p>
        <p>Rationale</p>
        <p>This initiative is focused on building a global consensus around core diagnostic criteria for malnutrition in adults in clinical settings.</p>
        <p>Methods</p>
        <p>In January 2016, the Global Leadership Initiative on Malnutrition (GLIM) was convened by several of the major global clinical nutrition societies. GLIM appointed a core leadership committee and a supporting working group with representatives bringing additional global diversity and expertise. Empirical consensus was reached through a series of face‐to‐face meetings, telephone conferences, and e‐mail communications.</p>
        <p>Results</p>
        <p><anchor xml:id="a1"/>A two‐step approach for the malnutrition diagnosis was selected, i.e., first screening to identify “at risk” status by the use of any validated screening tool, and second, assessment for diagnosis and grading the severity of malnutrition. The malnutrition criteria for consideration were retrieved from existing approaches for screening and assessment. Potential criteria were subjected to a ballot among the GLIM core and supporting working group members. The top five ranked criteria included three phenotypic criteria (weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present.<anchor xml:id="a2"/> <anchor xml:id="a3"/>Phenotypic metrics for grading severity as Stage 1 (moderate) and Stage 2 (severe) malnutrition are proposed. It is recommended that the etiologic criteria be used to guide intervention and anticipated outcomes. The recommended approach supports classification of malnutrition into four etiology‐related diagnosis categories.<anchor xml:id="a4"/></p>
        <p>Conclusion</p>
        <p><anchor xml:id="a5"/>A consensus scheme for diagnosing malnutrition in adults in clinical settings on a global scale is proposed. Next steps are to secure further collaboration and endorsements from leading nutrition professional societies, to identify overlaps with syndromes like cachexia and sarcopenia, and to promote dissemination, validation studies, and feedback. The diagnostic construct should be re‐considered every 3–5 years.<anchor xml:id="a6"/></p>
        <p>Keywords: Malnutrition, Screening, Assessment, Diagnosis</p>
        <p>status released display-pdf yes is-olf no is-manuscript no is-preprint no is-journal-matter no is-scanned no is-retracted no Issue date 2019 Feb.</p>
        <p>1. Introduction</p>
        <p>Malnutrition due to disease, poverty, hunger, war, and natural catastrophe is a fate suffered by greater than 1 billion of the world&#x27;s population. Historically, starvation and famine were prevalent causes of malnutrition and they remain so today. However, with improvements in agriculture, education, public health, healthcare, and living standards, nutrition disorders and related conditions now encompass the full scope of undernutrition, micronutrient abnormalities, obesity, cachexia, sarcopenia, and frailty. 1 , 2</p>
        <p>Malnutrition, e.g. undernutrition, may be caused by compromised intake or assimilation of nutrients but there is growing appreciation that malnutrition may also be caused by disease‐associated inflammatory or other mechanisms. The malnutrition that is associated with disease or injury invariably consists of a combination of reduced food intake or assimilation and varying degrees of acute or chronic inflammation, leading to altered body composition and diminished biological function. 1 , 2 , 3 <anchor xml:id="a7"/>Inflammation contributes to malnutrition through associated anorexia and decreased food intake as well as altered metabolism with elevation of resting energy expenditure and increased muscle catabolism. Altered body composition manifests as a decrease in any marker of muscle mass (fat‐free mass, muscle mass index or body cell mass). Thus, malnutrition is associated with adverse functional and clinical outcomes.<anchor xml:id="a8"/></p>
        <p><anchor xml:id="a9"/>Although malnutrition is a global concern associated with incremental morbidity, mortality, and cost, there has been a fundamental lack of consensus on diagnostic criteria for application in clinical settings. No single existing approach has secured broad global acceptance. 1 , 4 , 5 , 6 , 7 , 8 Our evolving understanding of the contributions of disease/inflammation may render some concepts of malnutrition in the current International Classifications of Diseases (ICD‐10) ( http://www.who.int/classifications/icd/en/ ) inconsistent with approaches or nomenclature that are currently used in clinical practice and research.<anchor xml:id="a10"/> Thus, there is an urgent need to establish a global consensus to be used in clinical care settings for adults.</p>
        <p>In order to respond to the needs of the clinical nutrition and medical communities the Global Leadership Initiative on Malnutrition (GLIM) was convened in January 2016. GLIM has engaged several of the clinical nutrition societies with global reach to focus on standardizing the clinical practice of malnutrition diagnosis. We also sought to clarify overlaps with related disease classifications including cachexia. The purpose of this specific initiative is to reach global consensus on the identification and endorsement of criteria for the diagnosis of malnutrition in clinical settings.</p>
        <p>2. Methods</p>
        <p>2.1. The consensus procedure</p>
        <p>On January 19, 2016 the Global Leadership Conversation: Addressing Malnutrition was held at the ASPEN Conference. 9 Key breakthroughs at that meeting led to the development of GLIM:</p>
        <p>It was recognized that there was considerable consensus among stakeholders around many malnutrition diagnosis issues</p>
        <p>There was strong commitment for reaching broader global consensus in defining and characterizing malnutrition</p>
        <p>A core leadership committee with representatives of several of the global clinical nutrition societies; ASPEN ( www.nutritioncare.org ), ESPEN ( www.espen.org ), FELANPE ( www.felanpeweb.org ) and PENSA ( www.pensa‐online.org ) was constituted to form GLIM. The core GLIM leadership committee then created a larger supporting working group comprised of invited members that brought additional global diversity and expertise to the consensus effort.</p>
        <p>It was agreed that a series of face‐to‐face meetings, telephone conferences, and email communications would be used to delineate the GLIM approach.</p>
        <p>The first full meeting of the GLIM extended working group was held September 19, 2016 at the ESPEN Congress. Highlighted objectives included consensus development of evidence‐based criteria suitable to diverse clinical settings, global dissemination of consensus criteria, and the priority to seek adoption by leading diagnosis classification and coding entities across the globe. It was also agreed that the desired approach to malnutrition diagnosis should be simple and include clinically relevant diagnostic criteria that will be appropriate for application by all healthcare professionals using methods that are widely available. The intent was also to promote global use of consensus criteria that can be readily used with other approaches and additional criteria of regional preference.</p>
        <p>3. Results</p>
        <p>Consensus was gradually achieved over the course of the GLIM meetings held February 20, 2017 at the ASPEN Conference, 11 September 11, 2017 at the ESPEN Congress, and January 25, 2018 at the ASPEN Conference. Meanwhile, discussions were also held with the leadership of The Society of Sarcopenia, Cachexia and Wasting Disorders (SCWD).</p>
        <p>3.1. A two‐step model for risk screening and diagnosis assessment</p>
        <p><anchor xml:id="a11"/>There was strong consensus that the key first step in the evaluation of nutritional status is malnutrition risk screening to identify “at risk” status by the use of any validated screening tool 12 , 13 , 14 ; some of these tools are noted in Table  1 and the Appendix. This is followed by the second step of assessment for diagnosis and severity grading as described below.<anchor xml:id="a12"/></p>
        <p>Table 1 Survey of existing approaches used in screening and assessment of malnutrition and cachexia.</p>
        <p>NRS‐2002   12 , a</p>
        <p>MNA‐SF   21 , a   ,   b</p>
        <p>MUST   22 , a</p>
        <p>ESPEN 2015   8 , a</p>
        <p>ASPEN/AND   7 , a</p>
        <p>SGA   4 , a</p>
        <p>Evans 2008   5 , c</p>
        <p>PEW 2008   23 , d</p>
        <p>Fearon 2011   6 , c</p>
        <p>Etiologies</p>
        <p>Reduced food intake X X X X X X X X</p>
        <p>Disease burden/inflammation X X X X X X X X X</p>
        <p>Symptoms</p>
        <p>Anorexia X X X X</p>
        <p>Weakness X X X</p>
        <p>Signs/Phenotype</p>
        <p>Weight loss X X X X X X X X X</p>
        <p>Body mass index X X X X X X X</p>
        <p>Lean/fat free/muscle mass X X X X X X X</p>
        <p>Fat mass X X X</p>
        <p>Fluid retention/ascites X X</p>
        <p>Muscle function; e.g. grip strength X X X</p>
        <p>Biochemistry X X</p>
        <p>NRS‐2002: Nutritional Risk Screening‐2002, MNA‐SF = Mini Nutritional Assessment‐Short Form, MUST = Malnutrition Universal Screening Tool, ESPEN = European Society for Clinical Nutrition and Metabolism, ASPEN = American Society of Parenteral and Enteral Nutrition, AND = Academy of Nutritiona and Dietetics, SGA = Subjective Global Assessment, PEW=Protein Energy Wasting</p>
        <p>a Malnutrition approach</p>
        <p>b Adapted for older adults</p>
        <p>c Cachexia approach</p>
        <p>d Adapted for chronic kidney disease</p>
        <p>3.2. Criteria selected for malnutrition diagnosis</p>
        <p><anchor xml:id="a13"/>A comprehensive survey of existing approaches used in screening and assessment of malnutrition was conducted to identify criteria worthy of consideration (Table  1 and the Appendix). It was recognized that these approaches incorporate multiple common criteria. For example, the presence of weight loss and disease burden or inflammation is common to most of them as is reduced food intake (Table  1 ).<anchor xml:id="a14"/> Potential consensus criteria from existing approaches as well as additional criteria suggested by participants were subject to further consideration.</p>
        <p>In order to establish consensus and endorsement of a minimum set of diagnostic criteria by the core leadership committee and the supporting working group a formal ballot was administered whereby participants ranked proposed diagnosis criteria. The top 5 ranked criteria by an overwhelming majority of GLIM participants were as follows:</p>
        <p>Weight loss</p>
        <p>Low body mass index (BMI)</p>
        <p>Reduced muscle mass</p>
        <p>Reduced food intake or assimilation</p>
        <p>Disease burden/inflammation</p>
        <p>3.3. Weight loss</p>
        <p>There was strong GLIM consensus for the inclusion of weight loss as a phenotypic criterion. Validity is well established and there is a robust literature on which threshold selection could be based (Appendix). There must be priority to obtain repeated weight measures over time to identify trajectories of decline, maintenance, and improvement. GLIM participants felt that it is especially important to recognize the pace of weight loss early in the course of disease or injury and to highlight that many patients will have lost appreciable weight prior to presenting to the healthcare.</p>
        <p>3.4. Low BMI</p>
        <p><anchor xml:id="a15"/>There is substantial regional variation in the use of low BMI as a phenotypic criterion for malnutrition diagnosis. North American GLIM representatives indicated that low BMI is seldom used as a clinical malnutrition marker in those regions. The experience from the current American population is that people are often overweight or obese and would need to lose substantial weight before low BMI designation would occur. Since other regions of the world currently make use of BMI as a criterion for recognition of malnutrition, the GLIM consensus includes low BMI. Further research is however needed to secure consensus reference BMI data for Asian populations in clinical settings.<anchor xml:id="a16"/></p>
        <p>3.5. Reduced muscle mass</p>
        <p><anchor xml:id="a17"/>Reduced muscle mass is a phenotypic criterion with strong evidence to support its inclusion in the GLIM consensus criteria. However, there is not consensus regarding how best to measure and define reduced muscle mass, particularly in clinical settings. Therefore, GLIM recommends measurement by dual‐energy absorptiometry or other validated body composition measures such as bioelectrical impedance, ultrasound, computed tomography or magnetic resonance imaging, but these methods are still not available in most settings for nutritional assessment throughout the globe.<anchor xml:id="a18"/> Physical examination or anthropometric measures of calf or arm muscle circumference are therefore included as alternative measures. Recommendations are likely to evolve as portable and less costly body composition technologies are developed and become widely available.</p>
        <p><anchor xml:id="a19"/>For the purpose of recommended cut‐off values for muscle mass reductions, GLIM refers to recommendations from the European Working Group on Sarcopenia in Older People (EWGSOP) 15 and from The Foundation of National Institute of Health (FNIH) initiative, 16 and the Asian Working Group on Sarcopenia (AWGS). Reference standards for muscle mass may warrant adjustment for race and sex. Additional research is warranted to establish general reference standards as well as for some specific populations, e.g. in Asia.<anchor xml:id="a20"/> Examples of recommended thresholds are found in Table  2 .</p>
        <p>Table 2 Examples of recommended thresholds for reduced muscle mass</p>
        <p>Males Females</p>
        <p>Appendicular Skeletal Muscle Index (ASMI, kg/m 2 ) 15   &lt;7.26 &lt;5.25</p>
        <p>ASMI, kg/m 2   24 , 1   &lt;7 &lt;6</p>
        <p>ASMI, kg/m 2   17 , 2</p>
        <p>‐ DXA &lt;7 &lt;5.4</p>
        <p>‐ BIA &lt;7 &lt;5.7</p>
        <p>Fat free mass index (FFMI, kg/m 2 ) 8   &lt;17 &lt;15</p>
        <p>Appendicular lean mass (ALM, kg) 25   &lt;21.4 &lt;14.1</p>
        <p>Appendicular lean mass adjusted for BMI = ALM/BMI 26   &lt;0.725 &lt;0.591</p>
        <p>DXA = dual energy x‐ray absorptiometry, BIA = bioelectrical impedance analysis</p>
        <p>BMI = body mass index</p>
        <p>1  Recommendations from European Working Group on Sarcopenia in Older People 2 (EWGSOP2); personal communication Alfonso Cruz‐Jentoft. Recommendations from Asian Working Group for Sarcopenia (AWGS) for Asians.</p>
        <p><anchor xml:id="a21"/>Assessment of muscle function using grip strength or other validated procedures is recommended as a supportive measure in the GLIM consensus (Tables  3 and 4 ). Decline in muscle strength generally exceeds changes in muscle size. 18 However, irrespective of etiology, appreciable loss of muscle mass is generally accompanied by reduced muscle function. In situations where muscle mass cannot be readily assessed then muscle strength, e.g. hand grip strength, is an appropriate supporting proxy.<anchor xml:id="a22"/></p>
        <p>Table 3 Phenotypic and etiologic criteria for the diagnosis of malnutrition.</p>
        <p>Phenotypic Criteria   *</p>
        <p>Etiologic Criteria   *</p>
        <p>Weight loss (%)</p>
        <p>Low body mass index (kg/m   2   )</p>
        <p>Reduced muscle mass   a</p>
        <p>Reduced food intake or assimilation   b   ,   c</p>
        <p>Inflammation   d   ,   e   ,   f</p>
        <p>&gt;5% within past 6 months, or&gt;10% beyond 6 months  <anchor xml:id="a23"/>&lt;20 if &lt;70 years, or  &lt;22 if &gt;70 years Reduced by validated body composition measuring techniques a</p>
        <p>≤50% of ER &gt;1 week, or any reduction for &gt;2 weeks, or  any chronic GI condition that adversely impacts food assimilation or absorption b   ,   c   Acute disease/injury d   ,   f or chronic disease‐related e   ,   f</p>
        <p>Asia:  &lt;18.5 if &lt;70 years, or  &lt;20 if &gt;70 years<anchor xml:id="a24"/></p>
        <p>*  Requires at least 1 phenotypic criterion and 1 etiologic criterion for diagnosis of malnutrition.</p>
        <p>a  For example fat free mass index (FFMI, kg/m 2 )) by dual‐energy absorptiometry (DXA) or corresponding standards using other body composition methods like bioelectrical impedance analysis (BIA), CT or MRI. When not available or by regional preference, physical examination or standard anthropometric measures like mid‐arm muscle or calf circumferences may be used. Thresholds for reduced muscle mass need to be adapted to race (Asia). Functional assessments like hand‐grip strength may be considered as a supportive measure.</p>
        <p>b  Consider gastrointestinal symptoms as supportive indicators that can impair food intake or absorption e.g. dysphagia, nausea, vomiting, diarrhea, constipation or abdominal pain. Use clinical judgement to discern severity based upon the degree to which intake or absorption are impaired. Symptom intensity, frequency, and duration should be noted.</p>
        <p>c  Reduced assimilation of food/nutrients is associated with malabsorptive disorders like short bowel syndrome, pancreatic insufficiency and after bariatric surgery. It is also associated with disorders like esophageal strictures, gastroparesis, and intestinal pseudo‐obstruction. Malabsorption is a clinical diagnosis manifest as chronic diarrhea or steatorrhea. Malabsorption in those with ostomies is evidenced by elevated volumes of output. Use clinical judgement or additional evaluation to discern severity based upon frequency, duration, and quantitation of fecal fat and/or volume of losses.</p>
        <p>d  Acute disease/injury‐related. Severe inflammation is likely to be associated with major infection, burns, trauma or closed head injury. Other acute disease/injury‐related conditions are likely to be associated with mild to moderate inflammation.</p>
        <p>e  Chronic disease‐related. Severe inflammation is not generally associated with chronic disease conditions. Chronic or recurrent mild to moderate inflammation is likely to be associated with malignant disease, chronic obstructive pulmonary disease, congestive heart failure, chronic renal disease or any disease with chronic or recurrent Inflammation. Note that transient inflammation of a mild degree does not meet the threshold for this etiologic criterion.</p>
        <p>f  C‐reactive protein may be used as a supportive laboratory measure.</p>
        <p>GI = gastro‐intestinal, ER = energy requirements</p>
        <p>Table 4 Thresholds for severity grading of malnutrition into stage 1 (moderate) and stage 2 (severe) malnutrition</p>
        <p>Phenotypic Criteria   a</p>
        <p>Weight loss (%)</p>
        <p>Low body mass index (kg/m   2   )   b</p>
        <p>Reduced muscle mass   c</p>
        <p>Stage 1/Moderate Malnutrition</p>
        <p>(Requires 1 phenotypic criterion that meets this grade)  5–10% within the past 6 mo, or  10–20% beyond 6 mo &lt;20 if &lt;70 yr, &lt;22 if ≥70 yr Mild to moderate deficit (per validated assessment methods – see below)</p>
        <p>Stage 2/Severe Malnutrition</p>
        <p>(Requires 1 phenotypic criterion that meets this grade)  &gt;10% within the past 6 mo, or  &gt;20% beyond 6 mo  &lt;18.5 if &lt;70 yr, &lt;20 if ≥70 yr Severe deficit (per validated assessment methods – see below)</p>
        <p>a Severity grading is based upon the noted phenotypic criteria while the etiologic criteria described in the text and Figure  1 are used to provide the context to guide intervention and anticipated outcomes.</p>
        <p>b Further research is needed to secure consensus reference BMI data for Asian populations in clinical settings.</p>
        <p>c For example appendicular lean mass index (ALMI, kg/m 2 ) by dual‐energy absorptiometry or corresponding standards using other body composition methods like bioelectrical impedance analysis (BIA), CT or MRI. When not available or by regional preference, physical examination or standard anthropometric measures like mid‐arm muscle or calf circumferences may be used. Functional assessments like hand‐grip strength may be used as a supportive measure. 15</p>
        <p>3.6. Reduced food intake or assimilation</p>
        <p>Reduced food intake is a well‐established etiologic criterion for malnutrition that has strong validity. It can have multiple causes including poor oral health, medication side effects, depression, dysphagia, gastrointestinal complaints, anorexia and inadequate nutrition support. Thresholds for relevant impairment of food intake are widely reported (Appendix) and GLIM participants sought to empirically provide a practical synthesis. Reduced assimilation of food/nutrients is associated with malabsorptive disorders like short bowel syndrome, pancreatic insufficiency and after bariatric surgery. It is also associated with disorders like esophageal strictures, gastroparesis, and intestinal pseudo‐obstruction, as well as with gastrointestinal symptoms like dysphagia, nausea, vomiting, diarrhea, constipation, and abdominal pain. These symptoms have been incorporated as supportive indicators into this GLIM consensus criterion to help to identify poor food intake or assimilation.</p>
        <p>3.7. Disease burden/inflammation</p>
        <p><anchor xml:id="a25"/>GLIM members recognized that disease burden/inflammation has become a widely accepted etiologic criterion in existing screening and assessment tools (Table  1 ). Clinical diagnosis provides a simple approach to recognition of severe, chronic or frequently recurrent inflammation. 1 , 2 , 19 For example, major infections, burns, trauma, and closed head injury are associated with acute inflammation of a severe degree. Indicators of inflammation may include fever, negative nitrogen balance, and elevated resting energy expenditure. Most chronic organ diseases, like congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, chronic kidney or liver disease and cancer, are associated with chronic or recurrent inflammation of a mild to moderate degree. While severe inflammation is generally easy to discern, clinical judgement is often required to recognize that of lesser degree.<anchor xml:id="a26"/> Supportive proxy measures of inflammation can include laboratory indicators like serum C‐reactive protein (CRP), albumin, or pre‐albumin.</p>
        <p>3.8. Approach to using combined phenotypic and etiologic criteria for malnutrition diagnosis</p>
        <p><anchor xml:id="a27"/>Weight loss, reduced BMI, and reduced muscle mass were categorized as phenotypic criteria, and reduced food intake/assimilation and disease burden/inflammation as etiologic criteria (Table  3 and Figure  1 ). For the diagnosis of malnutrition, GLIM recommends that the combination of at least one phenotypic criterion and one etiologic criterion is required (Table  3 and Figure  1 ). The selection of threshold values for the consensus diagnostic criteria was guided by review of existing approaches used in screening and assessment as was the selection of threshold values for severity grading described below (see Appendix). The selected threshold values for diagnosis of malnutrition are shown in Table  3 . While only the phenotypic criteria are proposed for the severity grading that follows, the inclusion of the etiologic criteria for malnutrition diagnosis is deemed a priority to guide appropriate intervention and anticipated outcomes.<anchor xml:id="a28"/></p>
        <p>Figure 1 GLIM diagnostic scheme for screening, assessment, diagnosis and grading of malnutrition.</p>
        <p>3.9. Severity grading of malnutrition</p>
        <p><anchor xml:id="a29"/>It is clinically useful to categorize the severity of malnutrition depending on the degree of aberration from established thresholds. Suggested phenotypic metrics for grading severity as Stage 1 (moderate) and Stage 2 (severe) malnutrition are shown in Table  4 .<anchor xml:id="a30"/></p>
        <p>3.10. Etiology‐based diagnosis classification</p>
        <p><anchor xml:id="a31"/>An etiology‐based diagnosis classification is endorsed by GLIM consistent with those suggested previously by the International Consensus Guideline Committee, 1 the AND/ASPEN Guidelines, 7 and the ESPEN Guidelines. The classification includes malnutrition related to chronic disease with inflammation, malnutrition related to chronic disease with minimal or no perceived inflammation, malnutrition related to acute disease or injury with severe inflammation, and malnutrition related to starvation including hunger/food shortage associated with socioeconomic or environmental factors (Table  5 ).<anchor xml:id="a32"/></p>
        <p>Table 5 Diagnosis category according to underlying etiology</p>
        <p>Malnutrition related to</p>
        <p>• Chronic disease with inflammation  • Chronic disease with minimal or no perceived inflammation  • Acute disease or injury with severe inflammation  • Starvation including hunger/food shortage associated with socio‐economic or environmental factors</p>
        <p>4. Discussion</p>
        <p>This GLIM initiative targets the priority to adopt global consensus criteria so that malnutrition prevalence, interventions, and outcomes may be compared throughout the world. A common malnutrition “language” is a paramount necessity in order to support the development of global standards of care that will promote improved outcomes. The proposed approach for diagnosing malnutrition is based upon a strong consensus endorsing core phenotypic and etiologic criteria that are already in widespread use throughout the world. The intent is to promote global use of these criteria that may in turn be readily used with other approaches and additional criteria of regional preference. The consensus criteria are intended to be simple and readily applied by clinicians and other health practitioners using tools and methods that are readily available. Only modest training should be required. The proposed approach encompasses risk screening and diagnosis but does not entail the robust detail of comprehensive nutrition assessment. It will provide a malnutrition diagnosis that may then be complemented by more comprehensive assessments to provide the basis for individualized care and treatment plans. Consultation of skilled nutrition practitioners like dietitians is recommended for comprehensive assessment based upon regional preferences and availability. Repeated criterion measures over time are recommended so that trajectories of decline, maintenance, and improvement may be identified.</p>
        <p><anchor xml:id="a33"/>The recommended GLIM approach encompasses both phenotypic and etiologic criteria for the diagnosis of malnutrition but uses only phenotypic criteria cut‐points to provide for severity grading. While etiology has not generally been included in criteria supporting the diagnosis of medical conditions in the ICD construct, the inclusion of etiology has been widely adopted in the clinical nutrition community because it serves to guide appropriate interventions and expected outcomes. For example, the presence of disease‐associated inflammatory response has potential for major impacts upon treatment approach and anticipated outcome.<anchor xml:id="a34"/> The GLIM approach acknowledges the diversity and the multi‐factorial etiologies underlying the development of the malnourished phenotype irrespective of body morphology – lean, normal or obese.</p>
        <p>Impairment of muscle strength and function are core phenomena in conditions like sarcopenia, 15 , 16 cachexia, 5 , 6 and frailty. Assessment of muscle strength should be an integral measure in assessment of patients with suspected sarcopenia since impairment of muscle strength is now recognized as a key component for diagnosis of sarcopenia. 15 , 16 Though inflammatory mediators and other mechanisms besides malnutrition are at play, it is recommended that the GLIM consensus criteria be applied to diagnose malnutrition in persons with sarcopenia, cachexia, and frailty so that the priority to undertake appropriate nutrition interventions may be recognized. The most helpful approaches for these conditions will however require combined multimodal interventions beyond nutritional supplements, like pharmacological agents and exercise.</p>
        <p><anchor xml:id="a35"/>Similarly, patients with cachexia will meet GLIM consensus criteria for malnutrition related to chronic disease with inflammation. Since there is concern that inclusion of cachexia with other disease‐related malnutrition conditions may diminish appreciation for some distinctive features of cachexia, there has been understandable hesitation by some to equate cachexia with this GLIM diagnosis category. The GLIM consensus criteria for malnutrition are therefore intended to be used in parallel with established concepts and nomenclature, including for example, those of cachexia, sarcopenia and frailty.<anchor xml:id="a36"/></p>
        <p>5. Conclusion</p>
        <p>A strong GLIM consensus endorsed the selected core phenotypic and etiologic criteria that are already in widespread use throughout the world. <anchor xml:id="a37"/>Many studies provide clear evidence that the agreed upon criteria for diagnosis of malnutrition are highly relevant and each of them alone is able to predict adverse clinical outcomes.<anchor xml:id="a38"/> Since these criteria may be readily used with other approaches and additional criteria of regional preference, their global adoption is more likely. As the initiative moves forward the creation of databases that use the selected criteria will facilitate the comparison of malnutrition prevalence, interventions, and outcomes throughout the world. Such observations can be used to support the development of global standards of care that will promote improved outcomes.</p>
        <p><anchor xml:id="a39"/>After the launch of the GLIM consensus it is important that the nutrition community use the criteria both in prospective and retrospective cohort studies as well as clinical trials in order to validate its relevance for clinical practice. Next steps are to secure endorsements from leading nutrition professional societies and to promote dissemination, validation testing, and feedback.<anchor xml:id="a40"/> The GLIM consensus should be re‐evaluated based upon review of new studies and advances in screening and assessment every 3–5 years. <anchor xml:id="a41"/>We will also seek to share the GLIM consensus recommendations with the World Health Organization in the context of the International Classification of Diseases revision process (ICD‐11). This is a high priority since this classification scheme guides clinical diagnosis and reimbursement across much of the world.<anchor xml:id="a42"/> The proposed GLIM consensus criteria target adults in clinical settings but it will also be a priority to work with the World Health Organization and the United Nations to explore the potential for use in other global settings like famine.</p>
        <p>Conflict of interest</p>
        <p>Gordon L Jensen: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>Tommy Cederholm: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>M. Isabel T.D. Correia: Conflicts of interest/ financial disclosures‐ none.</p>
        <p>M. Christina Gonzalez: Conflicts of interest/ financial disclosures‐ none.</p>
        <p>Ryoji Fukushima: Research grant from Taiho Pharmaceutical Factory, Inc.; Honoraria from Otsuka Pharmaceutical Factory, Inc., Terumo Corporation, and Abbotte Japan Co., Ltd.</p>
        <p>Takashi Higashiguchi: Conflicts of interest/ financial disclosures‐ none.</p>
        <p>Gertrudis Adrianza de Baptista: Conflicts of interest/ financial disclosures ‐ none.</p>
        <p>Rocco Barazzoni: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>Renée Blaauw: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>Andrew JS Coats: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>Adriana Crivelli: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>David C Evans: Paid for consulting by Coram / CVS Infusion (Parenteral Nutr. Advisory Board) and Lyric; Abbott Nutrition and Lyric both paid Evan&#x27;s institution for research grants; Paid by Abbott Nutrition for speaking honoraria.</p>
        <p>Leah Gramlich: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>Vanessa Fuchs‐Tarlovsky: Hospital General de México, Mexico City (honoraria and travel expenses),Tata Memorial Hospital India (travel expenses), UPAEP (Puebla Autonomus University – travel expenses); professional societies including FELANPE, PENSA, the Academy of Nutrition and Dietetics, and the Colegio Mexicano de Nutriologos (travel expenses); and an industry sponsor Fresenius Kabi (travel expenses).</p>
        <p>Heather Keller: Paid by Nestle Health Sciences for Manuscript focused on dysphagia; Paid for development of educational presentations including service on speakers’ bureaus by Abbott Nutrition and Nestle Health Sciences; Travel/accommodations expenses covered or reimbursed by Abbott Nutrition.</p>
        <p>Luisito Llido: Conflicts of interest/ financial disclosures ‐ none.</p>
        <p>Ainsley Malone: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>Kris M Mogensen: Board membership with ThriveRx; Consultancy from Pfizer, Employment with Brigham and Women&#x27;s Hospital, Honoraria from Abbott Nutrition Health Institute and Baxter, Royalties from Wolf Rinke Associates.</p>
        <p>John E Morley: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>Maurizio Muscaritoli: Conflicts of interest/ financial disclosures‐ none.</p>
        <p>Ibolya Nyulasi: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>Matthias Pirlich: Consultancy from seca GmbH, Hamburg, Germany.</p>
        <p>Veeradej Pisprasert: Conflicts of interest/ financial disclosures‐ none.</p>
        <p>Marian de van der Schueren: Conflicts of interest/ financial disclosures ‐ none.</p>
        <p>Soranit Siltharm: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>Pierre Singer: Grants from Baxter, B Braun, Abbott, and Fresenius Kabi; Honoraria from Baxter, B Braun, Fresenius Kabi, GE, and Cosmed.</p>
        <p>Kelly A. Tappenden: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>Nicolas Velasco: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>Preyanuj Yamwong: Conflicts of interest/ financial disclosures‐ none.</p>
        <p>Jianchun Yu: Conflicts of interest/ financial disclosures e none.</p>
        <p>Dan L. Waitzberg: Paid by Fresenius‐Kabi as a member of Member of the Felanpe Award; Paid by Danone for Overview of enteral nutrition in healing manuscript preparation; Travel expenses paid for by Fresenius‐Kabi and Nestle for Aspen and Espen conferences in 2018.</p>
        <p>Andre Van Gossum: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>Charlene Compher: Conflicts of interest/ financial disclosures ‐none.</p>
        <p>GLIM Core Leadership Committee</p>
        <p>Representing American Society for Parenteral and Enteral Nutrition (ASPEN): Gordon L. Jensen, Charlene Compher</p>
        <p>Representing European Society for Clinical Nutrition and Metabolism (ESPEN): Tommy Cederholm, Andre Van Gossum</p>
        <p>Representing Federacion Latinoamericana de Terapia Nutricional, Nutricion Clinica Y Metabolismmo (FELANPE): Maria Isabel T.D. Correia, M. Cristina Gonzalez</p>
        <p>Representing Parenteral and Enteral Nutrition Society of Asia (PENSA): Ryoji Fukushima, Takashi Higashiguchi.</p>
        <p>GLIM Working Group (alphabetical order)</p>
        <p>Baptista G, Barazzoni R, Blaauw R, Coats A, Crivelli A, Evans DC, Gramlich L, Fuchs V, Keller H, Llido L, Malone A, Mogensen KM, Morley JE, Muscaritoli M, Nyulasi I, Pirlich M, Pisprasert V, de van der Schueren MAE, Siltharm S, Singer P, Tappenden K, Velasco N, Waitzberg D, Yamwong P, Yu J.</p>
        <p>Appendix A. Table A1 Cut‐offs suggested in the major screening tools.</p>
        <p>Phenotypic Criteria</p>
        <p>Etiologic Criteria</p>
        <p>Weight loss</p>
        <p>Low body mass index (kg/m   2   )</p>
        <p>Reduced muscle mass/muscle function</p>
        <p>Reduced food intake</p>
        <p>Severe disease/inflammation</p>
        <p>NRS‐2002   12</p>
        <p>Mild   &gt;5% in 3 mo NS NA 50–75% of required preceding week E.g. hip fracture, chronic disease</p>
        <p>Moderate   &gt;5% in 2 mo 18.5–20.5 NA 25–60% of required preceding week E.g. major abdominal surgery, stroke</p>
        <p>Severe   &gt;5% in 1 mo &lt;18.5 NA 0–25% of required preceding week E.g. head injury, bone marrow transplantation, intensive care</p>
        <p>MNA‐SF   a   ,21</p>
        <p>Mild   1–3 kg in last months 21–23 NS NS NS</p>
        <p>Moderate   “Does not know” 19–21 “Does not go out” Moderate loss of appetite past 3 mo Mild dementia</p>
        <p>Severe   &gt;3 kg last months &lt;19 Bed or chair bound Severe loss of appetite past 3 mo Acute disease past 3 mo, or severe dementia/depression</p>
        <p>MUST   22</p>
        <p>Medium risk   5–10% in 3–6 mo 18.5–20 NA NS NA</p>
        <p>High risk   &gt;10% in 3–6 mo &lt;18.5 NA Acute illness AND no food intake for &gt;5 d NA</p>
        <p>a Adapted for older adults (&gt;65 y)</p>
        <p>NRS‐2002 = Nutritional Risk Screening‐2002, MNA‐SF = Mini Nutritional Assessment‐Short Form, MUST = Malnutrition Universal Screening Tool, NA = not applicable, NS = not specified</p>
        <p>Table A2 Cut‐offs suggested in major diagnostic tools for malnutrition and cachexia.</p>
        <p>Phenotypic Criteria</p>
        <p>Etiologic Criteria</p>
        <p>Weight loss (%)</p>
        <p>Low body Mass Index (kg/m   2   )</p>
        <p>Reduced muscle mass/muscle function</p>
        <p>Reduced food intake</p>
        <p>Severe disease/inflammation</p>
        <p>SGA   4</p>
        <p>Moderate/Stage B   5–10% past 6 mo NA Mild to moderate deficits in function or muscle mass “Definite decrease” Yes</p>
        <p>Severe/Stage C   &gt;10% past 6 mo NA Severe deficit in function and muscle mass “Severe deficit” Yes</p>
        <p>Evans 2008   5</p>
        <p>Cachexia   &gt;5% in &lt;12 mo &lt;20 Low FFMI, decreased muscle strength “Anorexia” Increased CRP/IL6, low serum albumin (&lt;3.2 g/l)</p>
        <p>PEW 2008   23</p>
        <p>Protein‐energy wasting   &gt;5% in 3 mo, or &gt; 10% in &gt;6 mo &lt;23  Muscle mass down by 5% last 3 mo, or &gt; 10% in &gt;6 mo.  Reduced MAC Energy intake &lt;25 kcal/kg BW/d for &gt;2 mo  Chronic kidney disease,  Serum albumin &lt;3.8 g/dl</p>
        <p>Fearon 2011   6</p>
        <p>Precachexia   &lt;5% NA NA “Anorexia” Metabolic change</p>
        <p>Cachexia   &gt;5% in 6 mo (&gt;2%) &lt;20 (when WL &gt; 2%) Sarcopenia ‐ ASMI 7.26/5.45 kg/m 2 (m/w) when WL &gt;2% “Often reduced food intake” Cancer with catabolic drive (systemic inflammation)</p>
        <p>ASPEN/AND 2012   7</p>
        <p>Moderate   1–2% in 1 w to 20% in 1 y NA Mild muscle loss &lt;75% of ER for 7 d‐3 mo Yes</p>
        <p>Severe   &gt;2% in 1 week to &gt;20% in 1 year NA Moderate to severe muscle loss, or reduced grip strength &lt;50% of ER for &gt;5 d‐ &lt; 1 mo Yes</p>
        <p>ESPEN 2015   8</p>
        <p>Malnutrition   &gt;5% past 3 mo, or &gt; 10%  &lt;18.5, or  &lt;20 (&lt;70y)/ &lt;22(&gt;70y) FFMI &lt;15 kg/m 2 (f), &lt;17 kg/m 2 (m) According to any validated tool NA</p>
        <p>SGA = Subjective Global Assessment, NA = not applicable, NS = not specified, WL = weight loss, PEW = protein energy wasting, MAC = mid‐arm circumference, ASMI = appendicular skeletal muscle index from DEXA, FFMI = fat free mass index</p>
        <p>Cederholm, T. ,  Jensen, G. L. ,  Correia, M. I. T. D. ,  Gonzalez, M. C. ,  Fukushima, R. ,  Higashiguchi, T. ,  Baptista, G. ,  Barazzoni, R. ,  Blaauw, R. ,  Coats, A. J. S. ,  Crivelli, A. N. ,  Evans, D. C. ,  Gramlich, L. ,  Fuchs‐Tarlovsky, V. ,  Keller, H. ,  Llido, L. ,  Malone, A. ,  Mogensen, K. M. ,  Morley, J. E. ,  Muscaritoli, M. ,  Nyulasi, I. ,  Pirlich, M. ,  Pisprasert, V. ,  de van der Schueren, M. A. E. ,  Siltharm, S. ,  Singer, P. ,  Tappenden, K. ,  Velasco, N. ,  Waitzberg, D. ,  Yamwong, P. ,  Yu, J. ,  Van Gossum, A. ,  Compher, C. , and  GLIM Core Leadership Committee, GLIM Working Group (2019) GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. Journal of Cachexia, Sarcopenia and Muscle, 10: 207–217. 10.1002/jcsm.12383.</p>
        <p>*  <anchor xml:id="a43"/>This article was first co‐published in the journal Clinical Nutrition and in the Journal of Parenteral and Enteral Nutrition and is re‐published here. Minor differences in style may appear in each publication, but the article is substantially the same in each journal.<anchor xml:id="a44"/></p>
    </body>
  </text>
</TEI>
